After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel ...

Jack Khouri, MD, discusses data from a multicenter study of teclistamab in patients with relapsed/refractory multiple myeloma who had prior exposure to BCMA-directed therapy.

HealthDay News — Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), according to a study published online March 25 in the Journal ...

More talk and fewer pills are being employed to help Americans maintain their mental health, a new study says.

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential ...

Cancer survivor Julia Pallentino is spreading awareness about an emerging cancer treatment, which helped her recovery from a ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials ...

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current ...

A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.

Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma ...